Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
218 participants
INTERVENTIONAL
2007-05-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial Comparing the Laryngeal Tube Suction Disposable and the Supreme Laryngeal Mask Airway
NCT02856672
A Comparison of Fiberoptic Endotracheal Intubation Between the Intubating Laryngeal Tube Suction and the LMA Protector
NCT04618926
Ambu® Laryngeal Mask as an Intubation Conduit
NCT00272194
Laryngeal Mask Airway Supreme Versus Laryngeal Tube
NCT02252120
Comparison Between the Supreme Laryngeal Mask Airway and the Laryngeal Tube Suction During Spontaneous Ventilation
NCT02859922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The LMA generally provides an adequate airway, but certain problems remain. (1) In 8-33% of LMA placements, more than one attempt is required. (2) It is sometimes difficult to advance the LMA without extending the neck (which is contraindicated in some patients). (3) The device does not protect the airway from aspiration of gastric contents. (4) It does not provide an airtight seal around the larynx (the usual pressures causing leakage of gas being 15-20 cm H20). Consequently, the device functions poorly during positive-pressure ventilation. (5) The esophagus is included within the rim of the LMA in 10-15% of patients, directly exposing the esophagus to positive airway pressures. This often results in insufflation of the stomach and postoperative discomfort.
The ETC is a disposable double-lumen tube that combines the features of a conventional endotracheal tube with those of an esophageal obturator airway. It is appropriate for prehospital, intraoperative, and emergency use and is especially useful for patients in whom direct visualization of the vocal cords is not possible, patients with massive airway bleeding or regurgitation, limited access to the airway, and patients in whom neck movement is contraindicated. Ventilation with the ETC is possible with either tracheal or esophageal intubation, as its distal cuff seals off the esophagus to prevent aspiration of gastric contents. The ETC has a 6.9% incidence of placement failure and a failed ventilation rate of 21.1%.
The Laryngeal Tube Suction (LTS; VBM Medizintechnik; King Systems, Noblesville, IN) is a supra-glottic airway device designed to provide a more effective seal than the LMA, thus eliminating problems 3-5 described above. The insertion of the standard laryngeal tube is generally easy. The reported success rate of insertion of, and ventilation through, the laryngeal tube ranges from 92-100% for the earlier prototype and 97-100% for the newest version. It is a flexible, curved tube that passes through the mouth, advances posterior to the epiglottis, and terminates in the upper esophagus. The multi-use, double-lumen, silicon LTS is designed with ventilation outlets located between an oropharyngeal and an esophageal, low-pressure cuff. The second lumen allows for an orogastric tube to be passed through for gastric drainage and pressure release. Patients at risk of regurgitation now have an alternative to tracheal intubation. This device has been used in a number of patients by anesthesiologists in Europe. There are many published scientific abstracts in the use of the LTS. A disposable version of the LTS is now available, the LTS-D. The LTS-D offers the same benefits as the LTS, but being disposable, it also eliminates the risk of cross-infection.
The ProSeal Laryngeal Mask Airway (PLMA, LMA North America Inc.) is the pre-existing double-lumen supra-glottic device that allows gastric drainage and pressure release. Its design is based on the LMA with an added lumen. It is reusable. The ProSeal exhibits an unsuccessful ventilation rate of 9%, and a first time insertion failure of 12.7%. Currently, the ProSeal exhibits a 3% incidence of foldover during insertion that prevents it from functioning properly. Due to differences in design, we postulate that the LTS-D will have a lower incidence of foldover than the PLMA.
This clinical study has been designed to compare the ProSeal, ETC and LTS-D as to the ease of placement and ventilation during controlled ventilation, proper positioning, the seal pressure with each placement, the patency of the drain tube by suctioning and measuring stomach contents, and finally, any complications with their use. Fiberoptic observations through each device will provide information in relation to the epiglottis and the distal opening of the device.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LTS-D
All the cases were divided into one of the group LTS-D, PLMA, and ETC
LTS-D
supra-glottic airway device
ProSeal Laryngeal Mask Airway
All patients were divided into either LTS-D, PLMA, or the ETC group.
ProSeal Laryngeal Mask Airway
pre-existing double-lumen supra-glottic device
Esophageal Tracheal Combitube (ETC)
All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
Esophageal Tracheal Combitube (ETC)
disposable double-lumen tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LTS-D
supra-glottic airway device
ProSeal Laryngeal Mask Airway
pre-existing double-lumen supra-glottic device
Esophageal Tracheal Combitube (ETC)
disposable double-lumen tube
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both male and female patients will be included.
Exclusion Criteria
1. Obesity
2. Pregnancy
3. History of gastric regurgitation, heart burn, ileus or "full stomach"
4. History of low pulmonary compliance or high pulmonary resistance
5. Known history of difficult endotracheal intubation or signs suggesting the possibility of difficult intubation
6. Pharyngeal pathology or
7. Upper airway obstruction due to laryngeal pathology.
* Additionally, they will be excluded if they meet one of the contraindication criteria for the Combitube including:
1. Intact gag reflexes
2. Height \<4 feet
3. Central airway obstruction
4. Recent ingestion of caustic substances
5. Known esophageal pathology, or
6. Known latex allergy.
* They will also be excluded if any tracheal disease is present such as tracheal tumors, stenosis or previous tracheal surgery.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carin A. Hagberg
Professor and Chairman, Joseph C. Gable, MD Endowed Chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carin A. Hagberg, M.D.
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Medical School at Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Hermann Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC-MS-04-254
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.